Fundraising Fox

BiVACOR

Huntington Beach, US · Founded 2008 · Delaware corporation · 80 employees on LinkedIn · 2 known investors

Find your way into BiVACOR

278 people in our graph share verified history with the BiVACOR team — schools, employers, funds. One of them is your warm intro.

Bret L. Bostwickunlockedknows William Cohn · together at Baylor College of Medicine (overlapped)
×2knows the team · via Johnson & Johnson
×4knows the team · via Harvard Medical School
knows the team · via Baylor College of Medicine
×3knows the team · via Oberlin College
knows the team · via Sante Ventures

BiVACOR is a clinical-stage medical device company developing a Total Artificial Heart (TAH), an electro-mechanical rotary blood pump with a single magnetically levitated rotor that replaces both ventricles for patients with end-stage biventricular heart failure. The device is undergoing an FDA-approved first-in-human Early Feasibility Study as a bridge-to-transplant solution.

HardwareHealthtechMedical Devices

Founders & leadership

BiVACOR was founded in 2008 by Daniel Timms.

DTDaniel Timms
Daniel TimmsinFounder/CTO
JD
James DillonExecutive
TV
Tom VassiliadesExecutive
WCWilliam Cohn
William CohninChief Medical OfficerVenture Partner at Sante Ventures

Board

BC
Bihua ChenBoard director
PKPaul Kelly
Paul KellyinNon Executive DirectorFounding Partner and Director at OneVentures
MM
Matt MackeyBoard director
RK
Raymond KelleherBoard director
RW
Raymond W. CohenBoard director
JJ
Jeannette JoughinBoard director

Investors · 2

OneVenturesSydney · $3.3M – $13.2M

Also in the syndicate · 1

Cormorant Asset Managementlead

Funding

SEC filings, press & company announcements

$24M disclosed across 2 of 3 rounds · 2021–2024

▶$9MraisedAug 2024 · 3 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matt MackeyDirector
  • Raymond KelleherDirector
  • Daniel TimmsExecutive Officer, Director
  • Bihua ChenDirector
  • Raymond W. CohenDirector
  • Jeannette JoughinDirector
  • James DillonExecutive Officer, Director
  • Paul KellyDirector
Offering amount
$28M
Amount sold
$9M
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedFeb 2023 · 4 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • William E. CohnDirector
  • Jeannette JoughinDirector
  • Paul KellyDirector
  • Raymond KelleherDirector
  • Daniel TimmsExecutive Officer, Director
  • Matt MackeyDirector
  • Bihua ChenDirector
  • Tom VassiliadesExecutive Officer, Director
Offering amount
$36M
Amount sold
$15M
First sale
Feb 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
Syncardia66 shared keywordsSynCardia manufactures the world's first commercially approved total artificial heart for patients with end-stage heart failure awaiting transplant. The company develops and delivers mechanical circulatory support devices as alternatives to heart transplantation for critically ill patients.
UPMC42 shared keywordsUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
Uclahealth41 shared keywordsUCLA Health is a major academic health system providing patient care across five hospitals and 290 clinics in Southern California and the Central Coast, alongside research and medical education. The organization conducts pioneering research in oncology, transplantation, neurosurgery, and other specialties, having contributed to the development of numerous FDA-approved treatments.
Rf Surgical37 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.

Companies competing with BiVACOR for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$3M
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

OneVentures-backed artificial heart start-up BiVACOR rattles the tin for $100mafr.com · Mar 2025Houston-based artificial heart company snags $22M in fresh funds - InnovationMaphouston.innovationmap.com · May 2021BiVACOR® Closes $19 Million Series B and Awarded $3 Million SBIR Grant From the National Institutes of Health - BioSpacebiospace.com · May 2021

Frequently asked questions

What does BiVACOR do?
BiVACOR is a clinical-stage medical device company developing a Total Artificial Heart (TAH), an electro-mechanical rotary blood pump with a single magnetically levitated rotor that replaces both ventricles for patients with end-stage biventricular heart failure. The device is undergoing an FDA-approved first-in-human Early Feasibility Study as a bridge-to-transplant solution.
Who founded BiVACOR?
BiVACOR was founded by Daniel Timms in 2008.
Who are BiVACOR's investors?
BiVACOR's investors include OneVentures.
How much funding has BiVACOR raised?
BiVACOR has disclosed $24M raised across 2 of its 3 known rounds.
Where is BiVACOR headquartered?
BiVACOR is headquartered in Huntington Beach, US.